SI0758890T1 - - Google Patents

Info

Publication number
SI0758890T1
SI0758890T1 SI9530716T SI9530716T SI0758890T1 SI 0758890 T1 SI0758890 T1 SI 0758890T1 SI 9530716 T SI9530716 T SI 9530716T SI 9530716 T SI9530716 T SI 9530716T SI 0758890 T1 SI0758890 T1 SI 0758890T1
Authority
SI
Slovenia
Prior art keywords
migraine
scavenger
prophylactic
antagonist
inhibitor
Prior art date
Application number
SI9530716T
Other languages
English (en)
Inventor
Jes Olesen
Original Assignee
Jes Olesen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jes Olesen filed Critical Jes Olesen
Publication of SI0758890T1 publication Critical patent/SI0758890T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
SI9530716T 1994-05-11 1995-05-10 SI0758890T1 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94610027 1994-05-11
EP95918128A EP0758890B1 (en) 1994-05-11 1995-05-10 Use of no scavengers, inhibitors or antagonists in the treatment of migraine
PCT/IB1995/000415 WO1995031195A1 (en) 1994-05-11 1995-05-10 Use of no scavengers, inhibitors or antagonists in the treatment of migraine

Publications (1)

Publication Number Publication Date
SI0758890T1 true SI0758890T1 (tr) 2005-08-31

Family

ID=8218183

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530716T SI0758890T1 (tr) 1994-05-11 1995-05-10

Country Status (12)

Country Link
US (1) US6265441B1 (tr)
EP (1) EP0758890B1 (tr)
JP (2) JPH10500129A (tr)
AT (1) ATE291909T1 (tr)
AU (1) AU704059B2 (tr)
CA (1) CA2189762C (tr)
DE (1) DE69534118T2 (tr)
DK (1) DK0758890T3 (tr)
ES (1) ES2238074T3 (tr)
PT (1) PT758890E (tr)
SI (1) SI0758890T1 (tr)
WO (1) WO1995031195A1 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU734490B2 (en) * 1996-11-05 2001-06-14 Neuraxon Inc. A method for treating tension-type headache
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
AU1824300A (en) * 1998-11-23 2000-06-13 Linden Biotechnology, Inc. Combination products of a guanylate cyclase inhibitor and a local anesthetic forpain relief
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
US20080274206A1 (en) * 2004-10-07 2008-11-06 Ngen Pharmaceuticals N.V. Stabilised Oxygen Releasing Composition
WO2007009462A2 (en) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
US20090191283A1 (en) * 2008-01-24 2009-07-30 Oronsky Bryan Todd Treatment of headaches, neck pain, joint pain and inflammatory-type pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
FR2707494B1 (fr) 1993-07-02 1995-08-25 Roussel Uclaf Nouvelle utilisation de dérivés de la béta-naphtoquinone ainsi que de leurs sels.
US5807885A (en) * 1993-08-12 1998-09-15 Astra Aktiebolag Amidine derivatives with nitric oxide synthetase activities
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
AU682768B2 (en) * 1994-05-07 1997-10-16 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase

Also Published As

Publication number Publication date
AU704059B2 (en) 1999-04-15
JPH10500129A (ja) 1998-01-06
DK0758890T3 (da) 2005-04-18
CA2189762A1 (en) 1995-11-23
DE69534118T2 (de) 2006-02-09
EP0758890A1 (en) 1997-02-26
AU2417995A (en) 1995-12-05
EP0758890B1 (en) 2005-03-30
DE69534118D1 (de) 2005-05-04
CA2189762C (en) 2009-01-13
ES2238074T3 (es) 2005-08-16
PT758890E (pt) 2005-06-30
JP2007137906A (ja) 2007-06-07
ATE291909T1 (de) 2005-04-15
US6265441B1 (en) 2001-07-24
WO1995031195A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
GEP20074185B (en) Incclusion complexs of aryl- heterocyclic salts
CA2282654A1 (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
PL316658A1 (en) Novel application of serotonin antagonists
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
EP0772590A4 (en) THROMBIN INHIBITORS
NZ335981A (en) Ketobenzamides as calpain inhibitors
CA2180954A1 (en) Inhibitors of human plasmin derived from the kunitz domains
MY117798A (en) Use of a rapamycin derivative in vasculopathies and xenotransplantation
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
BG102818A (en) D-manitol and method for its preparation
SI0758890T1 (tr)
EP0992243A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT
BG100248A (en) Squalene synthetase inhibitors
BG102780A (en) Nasal application of agents for the treatment of delayed emesis fits
AP2003002855A0 (en) Inhibitor of monoamine uptake.
PL334498A1 (en) Application of pramiprexole in treating the restless legs syndrome
PT1303520E (pt) Compostos terapêuticos e métodos
PL314799A1 (en) Application of dimeticone in treating constipations
EP1009421A4 (en) PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation